The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

LUTS: Lower Urinary Tract Symptoms Pub Date : 2022-01-16 DOI:10.1111/luts.12423

Qihua Wang, Rami Alshayyah, Bo Yang

{"title":"The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis","authors":"Qihua Wang, Rami Alshayyah, Bo Yang","doi":"10.1111/luts.12423","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Desmopressin acetate was recommended for nocturia in benign prostatic hyperplasia (BPH) patients recently, but its effect and safety is still controversial. We aimed to establish a systematic review and meta-analysis to confirm its effect on symptom relief and adverse effects.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic search was performed in PubMed, Cochrane Library, EMBASE, Medline, Web of Science and Science Direct databases from January 2000 to October 2021 for controlled trials of BPH patients comparing oral desmopressin with control groups. The mean difference (MD) and odds ratio (OR) were meta-analyzed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Four articles with 500 patients were included. Significantly greater benefit was detected for the desmopressin group in the improvement of nocturia (<i>P</i> = .004), international prostate symptom score – storage (IPSS-S) (<i>P</i> = .03), and quality of life (QoL) (<i>P</i> = .04) scores. Patients treated with desmopressin were at higher risk than the control group for short-term adverse events (<i>P</i> < .001), including nausea (4.71%, <i>P</i> = .04), headache (20%, <i>P</i> < .00001), dizziness (5.88%, <i>P</i> = .02) and hyponatremia (4.71%, <i>P</i> = .04), but the long-term incidence might decrease.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Desmopressin acetate can reduce nocturia frequency and improve the IPSS-S and QoL score in BPH patients. Some adverse reactions of desmopressin, such as hyponatremia, headache, dizziness and nausea, may be mild and short-term. No significant difference of desmopressin was found in improving the overall IPSS score and maximum urine flow.</p>\n </section>\n </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LUTS: Lower Urinary Tract Symptoms","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/luts.12423","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background

Desmopressin acetate was recommended for nocturia in benign prostatic hyperplasia (BPH) patients recently, but its effect and safety is still controversial. We aimed to establish a systematic review and meta-analysis to confirm its effect on symptom relief and adverse effects.

Methods

A systematic search was performed in PubMed, Cochrane Library, EMBASE, Medline, Web of Science and Science Direct databases from January 2000 to October 2021 for controlled trials of BPH patients comparing oral desmopressin with control groups. The mean difference (MD) and odds ratio (OR) were meta-analyzed.

Results

Four articles with 500 patients were included. Significantly greater benefit was detected for the desmopressin group in the improvement of nocturia (P = .004), international prostate symptom score – storage (IPSS-S) (P = .03), and quality of life (QoL) (P = .04) scores. Patients treated with desmopressin were at higher risk than the control group for short-term adverse events (P < .001), including nausea (4.71%, P = .04), headache (20%, P < .00001), dizziness (5.88%, P = .02) and hyponatremia (4.71%, P = .04), but the long-term incidence might decrease.

Conclusion

Desmopressin acetate can reduce nocturia frequency and improve the IPSS-S and QoL score in BPH patients. Some adverse reactions of desmopressin, such as hyponatremia, headache, dizziness and nausea, may be mild and short-term. No significant difference of desmopressin was found in improving the overall IPSS score and maximum urine flow.

查看原文本刊更多论文

醋酸去氨加压素治疗良性前列腺增生患者夜尿的疗效和安全性:一项系统综述和荟萃分析

背景醋酸去氨加压素最近被推荐用于治疗良性前列腺增生(BPH)患者夜尿症，但其疗效和安全性仍存在争议。我们的目的是建立一个系统的回顾和荟萃分析，以确认其对症状缓解和不良反应的影响。方法系统检索2000年1月至2021年10月PubMed、Cochrane Library、EMBASE、Medline、Web of Science和Science Direct数据库，比较口服去氨加压素与对照组的BPH患者对照试验。对平均差异(MD)和优势比(OR)进行meta分析。结果纳入文献4篇，500例患者。去氨加压素组在夜尿症(P = 0.004)、国际前列腺症状评分-存储(IPSS-S) (P = 0.03)和生活质量(QoL)评分(P = 0.04)改善方面获益显著。去氨加压素治疗组近期不良事件发生率高于对照组(P < 0.001)，包括恶心(4.71%，P = 0.04)、头痛(20%，P < 0.001)、头晕(5.88%，P = 0.02)、低钠血症(4.71%，P = 0.04)，但远期发生率可能降低。结论醋酸去氨加压素可减少前列腺增生症患者夜尿次数，改善患者IPSS-S和生活质量评分。去氨加压素的一些不良反应，如低钠血症、头痛、头晕和恶心，可能是轻微和短期的。去氨加压素在改善总IPSS评分和最大尿流量方面无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

LUTS: Lower Urinary Tract Symptoms UROLOGY & NEPHROLOGY-

CiteScore

3.00

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： LUTS is designed for the timely communication of peer-reviewed studies which provides new clinical and basic science information to physicians and researchers in the field of neurourology, urodynamics and urogynecology. Contributions are reviewed and selected by a group of distinguished referees from around the world, some of whom constitute the journal''s Editorial Board. The journal covers both basic and clinical research on lower urinary tract dysfunctions (LUTD), such as overactive bladder (OAB), detrusor underactivity, benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), urinary incontinence, pelvic organ prolapse (POP), painful bladder syndrome (PBS), as well as on other relevant conditions. Case reports are published only if new findings are provided. LUTS is an official journal of the Japanese Continence Society, the Korean Continence Society, and the Taiwanese Continence Society. Submission of papers from all countries are welcome. LUTS has been accepted into Science Citation Index Expanded (SCIE) with a 2011 Impact Factor.